{"id":819003,"date":"2025-02-27T07:12:27","date_gmt":"2025-02-27T12:12:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/"},"modified":"2025-02-27T07:12:27","modified_gmt":"2025-02-27T12:12:27","slug":"nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/","title":{"rendered":"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">Z\u00dcRICH, <span class=\"xn-location\">Switzerland<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"http:\/\/www.nlspharma.com\/\" target=\"_blank\" rel=\"nofollow\">NLS Pharmaceutics Ltd.<\/a> (Nasdaq: NLSP) (Nasdaq: NLSPW) (&#8220;NLS&#8221; or the &#8220;Company&#8221;), in collaboration with Aexon Labs Inc. (&#8220;Aexon Labs&#8221;), is pleased to announce new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist (&#8220;DOXA&#8221;) for narcolepsy and related neurological disorders. These results build upon the Company&#8217;s multi-target neurodegenerative strategy, which also includes AEX-41, demonstrating a novel and promising approach to addressing sleep disorders, neuroinflammation, and metabolic dysfunction.<\/p>\n<p>\n        <b>Key Preclinical Findings on AEX-2 (20 mg\/kg, IP)<\/b>\n      <\/p>\n<p>Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds, including AEX-41 and AEX-2, in redefining sleep-wake regulation and neuroprotection. In orexin-deficient mouse models, these compounds exhibited strong wake-promoting effects and sleep-wake cycle stabilization, reinforcing their potential as next-generation therapeutics. Key findings include:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Wakefulness Enhancement<\/b>: AEX-2 significantly increased total wake duration while maintaining a stable wake architecture, avoiding excessive fragmentation.<\/li>\n<li>\n          <b>REM Sleep Preservation:<\/b> Unlike traditional stimulants, AEX-2 regulated rapid eye movement (&#8220;REM&#8221;) sleep dynamics, minimizing undesired suppression and sleep rebound effects.<\/li>\n<li>\n          <b>Reduction in Cataplexy<\/b>: AEX-2 effectively reduced the frequency and duration of cataplexy episodes, a crucial advancement for treating narcolepsy type 1 (NT1).<\/li>\n<\/ul>\n<p>These data underscore the potential of AEX-2 as a safer and more targeted alternative to existing orexin-based therapies, such as TAK-994 and TAK-861, which have been hindered by safety concerns.<\/p>\n<p>\n        <b>Expanding the AEX Platform: AEX-2 and AEX-41 in Neurodegeneration and Metabolic Disorders<\/b>\n      <\/p>\n<p>Beyond narcolepsy, NLS Pharmaceutics and Aexon Labs are advancing AEX-2 and AEX-41 into new therapeutic areas, leveraging their multi-target mechanisms that extend to neuroinflammatory and metabolic pathways.<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Targeting\u00a0Neuroinflammation:<\/b> Recent discoveries highlight AEX compounds&#8217; engagement with the Sigma-1 receptor, which plays a key role in neuroprotection, synaptic plasticity, and REM sleep regulation.<\/li>\n<li>\n          <b>Potential in ALS and Neurodegenerative Diseases:<\/b> Sigma-1 receptor modulation, combined with orexin receptor activation, suggests AEX-41 may have applications in ALS and Parkinson&#8217;s disease, particularly in preserving motor function and reducing neuroinflammation.<\/li>\n<li>\n          <b>Addressing Diabetes-Associated Neurological Disorders (&#8220;DANS&#8221;):<\/b> Given the link between orexin signalling, metabolic regulation, and sleep disorders, the multi-target properties of DOXA compounds such as AEX-2 and AEX-41 could provide new therapeutic avenues for diabetes-related neuropathy and cognitive decline.<\/li>\n<\/ul>\n<p>Aexon Labs, known for its cutting-edge computational chemistry and AI-driven drug discovery, has played a key role in optimizing these multi-target molecules, ensuring high blood-brain barrier penetration and selective receptor affinity.<\/p>\n<p>\n        <b>Future Directions: Unlocking Multi-target Potential<\/b>\n      <\/p>\n<p>Building on these breakthrough findings, NLS Pharmaceutics is advancing AEX-2 and AEX-41 into IND-enabling studies in 2025, targeting first-in-human clinical trials by 2026.<\/p>\n<p>Beyond dual orexin receptor activation, these compounds engage Sigma-1 receptor modulation, cathepsin inhibition, and mitochondrial regulation, reinforcing their first-in-class potential.<\/p>\n<p>To validate this multi-target strategy, additional preclinical studies are underway, including an ongoing DANS model, potentially broadening their applications beyond sleep disorders.<\/p>\n<p>&#8220;The recent preclinical findings represent a key milestone for our DOXA platform,&#8221;\u00a0<b>said\u00a0Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics.<\/b>\u00a0&#8220;These preliminary findings reinforce our commitment to developing neurodegenerative therapies that not only manage symptoms, but also address the underlying mechanisms of sleep and neurodegenerative disorders. With ongoing studies in DANS, we are further expanding the potential of our multitarget approach to address metabolic dysfunction and its impact on brain health.&#8221;<\/p>\n<p>&#8220;We are encouraged by these recent preclinical results, which showcase the unique potential of our DOXA platform,&#8221; <b>said <span class=\"xn-person\">Alex Zwyer<\/span>, CEO of NLS Pharmaceutics<\/b>. &#8220;We believe these findings not only strengthen our commitment to developing transformative neurodegenerative therapies, but they also highlight the importance of addressing the underlying mechanisms associated with sleep and neurodegenerative disorders. As we continue our studies in DANS, we are optimistic about expanding the therapeutic landscape of our multi-target approach.&#8221;<\/p>\n<p>NLS Pharmaceutics plans to present the definitive results on AEX-2 and AEX-41 at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting, taking place <span class=\"xn-chron\">May 27-30, 2025<\/span>, at the Fairmont Scottsdale Princess in <span class=\"xn-location\">Scottsdale, Arizona<\/span>. NLS Pharmaceutics&#8217; poster presentation titled &#8220;Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary Results of AEX-41 and AEX-2 in a Mouse Model,&#8221; will be displayed on <span class=\"xn-chron\">May 27-30, 2025<\/span>.<\/p>\n<p>\n        <b>About Aexon Labs<\/b>\n      <\/p>\n<p>Aexon Labs is a\u00a0cutting-edge biotechnology company\u00a0specializing in\u00a0intelligente drug discovery and computational chemistry\u00a0to develop\u00a0next-generation therapeutics\u00a0for\u00a0sleep disorders, neurodegenerative diseases, and metabolic dysfunctions. Leveraging\u00a0advanced molecular modeling and multi-target drug design, Aexon Labs is at the forefront of\u00a0innovative compound development, integrating\u00a0dual orexin receptor activation, neuroinflammation modulation, and mitochondrial regulation.<\/p>\n<p>With a\u00a0strong focus on translational research, Aexon Labs is dedicated to pioneering\u00a0first-in-class therapies, including its\u00a0non-sulfonamide dual orexin receptor agonist (DOXA) platform, designed to\u00a0restore sleep-wake balance, enhance neuroprotection, and improve metabolic homeostasis.<\/p>\n<p>For more information, visit\u00a0<b><a href=\"https:\/\/www.aexonlabs.com\/\" target=\"_blank\" rel=\"nofollow\">www.aexonlabs.com<\/a>.<\/b><\/p>\n<p>\n        <b>About NLS Pharmaceutics<\/b>\n      <\/p>\n<p>NLS Pharmaceutics is a global biopharmaceutical company\u00a0focused on developing\u00a0next-generation therapies\u00a0for\u00a0sleep disorders, neurodegenerative diseases, and metabolic dysfunctions. Through a\u00a0strategic licensing agreement with Aexon Labs, NLS is advancing a portfolio of\u00a0non-sulfonamide dual orexin receptor agonists (DOXA), including\u00a0AEX-2 and AEX-41, designed to\u00a0restore sleep-wake balance, reduce neuroinflammation, and address metabolic dysregulation. <a href=\"http:\/\/www.nlspharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.nlspharma.com<\/a><\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the DOXA platform, the potential safety and efficacy of\u00a0AEX-41 and\u00a0AEX-2, the development and potential applications of AEX-41 and AEX02 and timing thereof, plans to expand its research and timing thereof, and NLS&#8217; pipeline. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and\/or successfully completing its clinical trials; NLS products may not be approved by regulatory agencies, NLS technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS&#8217; process; NLS&#8217; products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS patents may not be sufficient; NLS products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading &#8220;Risk Factors&#8221; in NLS annual report on Form 20-F for the year ended <span class=\"xn-chron\">December 31, 2023<\/span> filed with the Securities and Exchange Commission (SEC), which is available on the SEC&#8217;s website, <a href=\"http:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a>, and in subsequent filings made by NLS with the SEC.<\/p>\n<p>\n        <b>NLS Contacts:<\/b>\n      <\/p>\n<p>\n        <a href=\"mailto:InvestorRelations@nls-pharma.com\" target=\"_blank\" rel=\"nofollow\">InvestorRelations@nls-pharma.com<\/a><br \/>\n        <br \/>\n        <a href=\"http:\/\/www.nlspharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.nlspharma.com<\/a>\n      <\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform-302387194.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform-302387194.html<\/a><\/p>\n<p>SOURCE  NLS Pharmaceutics Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN29033&amp;Transmission_Id=202502270700PR_NEWS_USPR_____LN29033&amp;DateId=20250227\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Z\u00dcRICH, Switzerland, Feb. 27, 2025 \/PRNewswire\/ &#8212; NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) (&#8220;NLS&#8221; or the &#8220;Company&#8221;), in collaboration with Aexon Labs Inc. (&#8220;Aexon Labs&#8221;), is pleased to announce new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist (&#8220;DOXA&#8221;) for narcolepsy and related neurological disorders. These results build upon the Company&#8217;s multi-target neurodegenerative strategy, which also includes AEX-41, demonstrating a novel and promising approach to addressing sleep disorders, neuroinflammation, and metabolic dysfunction. Key Preclinical Findings on AEX-2 (20 mg\/kg, IP) Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds, including AEX-41 and AEX-2, in redefining sleep-wake regulation and neuroprotection. In orexin-deficient mouse models, these compounds exhibited strong wake-promoting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819003","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Z\u00dcRICH, Switzerland, Feb. 27, 2025 \/PRNewswire\/ &#8212; NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) (&#8220;NLS&#8221; or the &#8220;Company&#8221;), in collaboration with Aexon Labs Inc. (&#8220;Aexon Labs&#8221;), is pleased to announce new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist (&#8220;DOXA&#8221;) for narcolepsy and related neurological disorders. These results build upon the Company&#8217;s multi-target neurodegenerative strategy, which also includes AEX-41, demonstrating a novel and promising approach to addressing sleep disorders, neuroinflammation, and metabolic dysfunction. Key Preclinical Findings on AEX-2 (20 mg\/kg, IP) Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds, including AEX-41 and AEX-2, in redefining sleep-wake regulation and neuroprotection. In orexin-deficient mouse models, these compounds exhibited strong wake-promoting &hellip; Continue reading &quot;NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T12:12:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform\",\"datePublished\":\"2025-02-27T12:12:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/\"},\"wordCount\":1265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN29033&amp;sd=2025-02-27\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/\",\"name\":\"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN29033&amp;sd=2025-02-27\",\"datePublished\":\"2025-02-27T12:12:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN29033&amp;sd=2025-02-27\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN29033&amp;sd=2025-02-27\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/","og_locale":"en_US","og_type":"article","og_title":"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Market Newsdesk","og_description":"PR Newswire Z\u00dcRICH, Switzerland, Feb. 27, 2025 \/PRNewswire\/ &#8212; NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) (&#8220;NLS&#8221; or the &#8220;Company&#8221;), in collaboration with Aexon Labs Inc. (&#8220;Aexon Labs&#8221;), is pleased to announce new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist (&#8220;DOXA&#8221;) for narcolepsy and related neurological disorders. These results build upon the Company&#8217;s multi-target neurodegenerative strategy, which also includes AEX-41, demonstrating a novel and promising approach to addressing sleep disorders, neuroinflammation, and metabolic dysfunction. Key Preclinical Findings on AEX-2 (20 mg\/kg, IP) Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds, including AEX-41 and AEX-2, in redefining sleep-wake regulation and neuroprotection. In orexin-deficient mouse models, these compounds exhibited strong wake-promoting &hellip; Continue reading \"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T12:12:27+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform","datePublished":"2025-02-27T12:12:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/"},"wordCount":1265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/","name":"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27","datePublished":"2025-02-27T12:12:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN29033&amp;sd=2025-02-27"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-potential-of-its-non-sulfonamide-dual-orexin-receptor-agonist-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819003"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819003\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}